A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Completed · Phase 2

Conditions studied: Advanced Pancreatic Cancer

In brief

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

Key facts

Study ID

NCT03336216

Run by

Bristol-Myers Squibb

People needed

205

Starts

2017-12-18

Expected to finish

2023-06-01

Last updated by the study team

2024-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have histological or cytological confirmed diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas, which has progressed on or after one line of chemotherapy
• ECOG Performance status 0-1
• Adequate organ functions
• Measurable disease

You may not qualify if…

• Suspected or known CNS metastasis
• Participants with active, known, or suspected autoimmune disease
• Uncontrolled or significant cardiovascular disease
• Prior exposure to selected immune cell-modulating antibody regimens

Where it is running

• Mayo Clinic in Rochester, Minnesota — Phoenix, Arizona, United States
• HonorHealth Research Institute — Scottsdale, Arizona, United States
• Local Institution - 0007 — Los Angeles, California, United States
• University Of Colorado — Aurora, Colorado, United States
• Florida Cancer Specialists - South — Fort Myers, Florida, United States
• Florida Cancer Specialists - North — St. Petersburg, Florida, United States
• Local Institution - 0001 — Baltimore, Maryland, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Dana Farber Cancer Institute. — Boston, Massachusetts, United States
• Local Institution - 0010 — Boston, Massachusetts, United States
• Washington University — St Louis, Missouri, United States
• Local Institution - 0012 — New York, New York, United States
• Local Institution - 0005 — New York, New York, United States
• Local Institution - 0006 — Philadelphia, Pennsylvania, United States
• Local Institution - 0009 — Pittsburgh, Pennsylvania, United States
• Tennessee Oncology Chattanooga — Nashville, Tennessee, United States
• Local Institution - 0013 — Dallas, Texas, United States
• Local Institution - 0011 — Houston, Texas, United States
• University Of Washington — Seattle, Washington, United States
• Cross Cancer Institute — Edmonton, Alberta, Canada
• Local Institution - 0037 — Kingston, Ontario, Canada
• Local Institution - 0035 — Toronto, Ontario, Canada
• Local Institution - 0041 — Herlev, Denmark
• Local Institution - 0032 — Heidelberg, Germany
• Local Institution - 0029 — Mannheim, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.